Category: Allergan Inc.Syndicate content

Abbott CEO chides critics of corporate inversions | Medtech Wall Street news for the week of July 21, 2014

July 24, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Allergan cuts 1,500 jobs, faces SEC complaint; A countdown to failure for Valeant's hostile $53B Allergan takeover; GE Healthcare idles for another quarter

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott CEO defends inversions amid corporate exodus furor

Allergan cuts 1,500 jobs, faces SEC complaint

July 21, 2014 by Arezu Sarvestani

Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.

Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

A countdown to failure for Valeant's hostile $53B Allergan takeover

July 18, 2014 by Arezu Sarvestani

Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.

A countdown to failure for Valeant's hostile $53B Allergan takeover

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014

July 17, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Ocular Therapeutix sets terms for IPO; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B; Exo-suit maker ReWalk files for $57.5M IPO; Intersect ENT sets terms for $65M IPO

Ocular Therapeutix sets terms for IPO

July 11, 2014 by Brad Perriello

Ocular Therapeutix sets terms for IPO

Covidien shareholder files class action lawsuit blocking company's merger with Medtronic | The week in medtech M&A

July 16, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B

Shareholder files class action lawsuit to block Covidien-Medtronic merger

July 11, 2014 by Brad Perriello

Allergan renews fight against hostile Valeant takeover

July 14, 2014 by Brad Perriello

Allergan renews its battle against an unsolicited, $53 billion takeover bid by Valeant Pharmaceuticals and hedge fund ally Pershing Square Capital Management, calling for more transparency about Valeant's business.

Allergan renews fight against hostile Valeant takeover

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Valeant, hedge fund look to oust Allergan board members | MassDevice.com On Call

July 8, 2014 by Brad Perriello

Valeant and Pershing Square Capital Management look to replace 6 members of Allergan's board with their own slate of directors.

MassDevice.com On Call

MASSDEVICE ON CALL — Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, asked Allergan (NYSE:AGN) shareholders today to oust Allergan's board and replace it with a slate of its own directors.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp